ArticleInternational journal of molecular sciences2026

Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma.

Salih Demir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.